LONGEVITY BIOTECH REPORT: MEDIA ASSETS (GOOGLE DRIVE)
LONGEVITY BIOTECH REPORT 2026: PRESS RELEASE
Investors pour over $30bn into longevity biotech companies
New report predicts a $617bn market by 2045, as funding nearly quadruples in 2025, with more than 1,000 programs already in human trials
London, UK — September 16, 2026 — Global investment in longevity biotech reached a record $18.4 billion in 2025, up from $4.7 billion the year before, according to a major new report from Longevity.Technology. With $12.1 billion already invested in 2026, investors and pharmaceutical companies are increasingly backing gerotherapeutics — therapies designed to target the biological processes that drive aging itself, rather than individual diseases — as a fast-growing therapeutic category.
Last year’s funding surge represents the strongest year of financing yet for a field that can now be considered part of mainstream pharmaceutical development. The Longevity Biotech Report argues that the sector is entering a growth phase, underpinned by a growing clinical pipeline, larger investment rounds and increasing interest from established pharmaceutical companies.
The report finds that the recent increase in capital is being driven primarily by investors making substantially larger, conviction-led bets on selected companies.
KEY FINDINGS AT A GLANCE
- $18.4bn invested in longevity biotech in 2025 (up from $4.7bn in 2024)
- $12.1bn already invested in 2026
- More than 1,000 drug programs in human trials
- ~$230bn in risk-adjusted peak sales from new therapies targeting current disease indications, under existing regulatory pathways
- $173bn in potential additional annual revenue from these new therapies once a gerotherapeutic regulatory pathway opens (~2035)
- $617bn potential global market by 2045
Longevity biotech is already a multibillion-dollar market
A bottom-up analysis of 3,036 current therapeutic assets estimates approximately $230bn in risk-adjusted peak annual sales from new therapies targeting existing disease indications and current regulatory approval pathways, before any longevity-specific approvals. This includes conditions like diabetes, cardiovascular disease, and neurological disorders.
The report argues that this established disease-focused pipeline will ultimately provide the route through which longevity-related gerotherapeutic interventions enter mainstream healthcare to prevent and reverse age-related disease.
The path to a $600bn+ market
The report sets out a data-linked thesis for how the longevity biotech market will grow through the opening of dedicated gerotherapeutic regulatory pathways, unlocking a further $173bn in additional annual revenue from these new therapies as they gain approval for broader longevity benefits.
The $617bn projection assumes first gerotherapeutic approvals around 2035, global adoption, pricing broadly comparable with today’s GLP-1 medicines, 35% peak uptake among eligible populations, and a ten-year period for the market to reach maturity.
“Rather than regulators suddenly approving a drug to ‘treat aging’, therapies will keep arriving the other way round: approved first for a recognized disease, then shown to deliver broader benefits tied to mitigating the hallmarks of aging,” said Phil Newman, founder and CEO of Longevity.Technology. “We’re already seeing it play out with GLP-1s, and it’s the same pattern across most companies in our report; new assets built for specific diseases today, with real potential for wider longevity applications tomorrow.”
“This isn’t hype chasing capital, it is capital following the science,” said Newman. “Executives at Novo Nordisk and Eli Lilly are now referring to their own GLP-1 blockbusters as longevity drugs, and in Washington the Reagan-Udall Foundation for the FDA has convened ARPA-H and XPRIZE Healthspan on exactly how to regulate what comes next. That’s the machinery of a serious industry turning.”
Big Pharma and venture capital converge
Big Pharma companies are increasingly securing access to longevity science and leading venture capital firms are backing the same platforms. Eli Lilly first took an equity stake in NewLimit, a biotechnology company developing epigenetic reprogramming therapies, in October 2025, and Lilly Ventures returned for the company’s $435 million Series C in June 2026 — a round led by Founders Fund alongside new investors Thrive Capital, Greenoaks and Quiet Capital and returning investor Kleiner Perkins, valuing NewLimit at $3.1 billion.
In July 2026, Takeda committed approximately $60 million in project initiation fees and near-term payments for access to Insilico Medicine’s AI-driven Pharma.AI platform, in a collaboration worth up to approximately $600 million in total including milestones, plus tiered royalties, with Takeda taking exclusive worldwide rights across its therapeutic areas of interest.
The report highlights a broader ‘buy not build’ pattern of large pharmaceutical companies making staged investment and licensing arrangements as an increasingly common alternative to in-house development.
Capital is concentrating on fewer, later-stage, already de-risked platforms, where specialist longevity funds increasingly do the pre-screening investment and Big Pharma’s own CVC arms and generalist crossover funds harvest from it later, at a premium.
What is 'longevity biotech'?
At its simplest, longevity biotech seeks to develop therapeutics that address the biological mechanisms responsible for aging and age-related disease, potentially allowing a single gerotherapeutic intervention to prevent, delay or reverse several conditions rather than tackling each disease independently. The report does not include supplements, wellness products or lifestyle interventions, and focuses exclusively on drug, biologic and regenerative programs with identifiable development and regulatory pathways.
“Aging is not a single disease; its underlying biological processes contribute to many chronic conditions,” said Dr. Dominik Duscher, physician-scientist and President and CEO of MuseCell Innovations. “Regenerative cell platforms are particularly compelling because one well-characterized technology can be investigated across multiple indications, while still requiring rigorous clinical evidence for each. This report helps quantify the clinical and commercial potential of that approach.”
Drawing on a proprietary dataset covering more than 760 biotech companies and 3,580 therapeutic assets globally, of which 3,036 were modelled in the bottom-up pipeline valuation, the Longevity Biotech Report was developed over more than 18 months of work by Longevity.Technology analysts.
The Longevity Biotech Report can be accessed for free at: longevity.technology/data/report/longevity-biotech-report-2026
About Longevity.Technology
Longevity.Technology is a UK-headquartered research, media and investment organisation exclusively focused on the longevity industry. Longevity.Technology bridges the gap between scientific advancements and investors, fostering collaboration among researchers, entrepreneurs, policymakers, and clinical practitioners to drive innovation and investment in healthspan extension and longevity.
NOTES TO EDITORS — SOURCES
- Gerotherapeutic regulatory meeting, 27 May 2026, convened by the Reagan-Udall Foundation for the FDA with ARPA-H and XPRIZE Healthspan — reaganudall.org
- NewLimit $435m Series C at a $3.1bn valuation, led by Founders Fund with Eli Lilly Ventures returning — blog.newlimit.com. Eli Lilly’s first investment came in a $45m round in October 2025 — blog.newlimit.com
- Takeda–Insilico Medicine collaboration, approximately $60m in initiation and near-term payments, up to approximately $600m in total, plus tiered royalties — insilico.com
- GLP-1s described as longevity drugs by senior Novo Nordisk and Eli Lilly figures — longevity.technology
Media assets
Assets available for download here, including:
- Media briefing pack, including quotes from industry reviewers
- PDF of the full report draft
- Images of key data charts
- Photos + titles of key stakeholders
MEDIA CONTACT:
Danny Sullivan